Table 2 Multivariable analysis of p53 nuclear staining and established baseline prognostic variables and their association with biochemical relapse, clinical relapse and prostate cancer-specific survival
From: p53 nuclear accumulation as an early indicator of lethal prostate cancer
% of p53-positive nuclei model HR (95% CI), p-value | p53 cluster model HR (95% CI), p-value | |||||
|---|---|---|---|---|---|---|
Variable | BCR | MR | PCSM | BCR | MR | PCSM |
Increasing p53 positive tumour nucleia | 1.2 (1.1–1.3) p = 0.006 | 1.4 (1.1–1.8) p = 0.007 | 1.9 (1.2–2.8) p = 0.003 | |||
p53 cluster Positive vs negative | 1.7 (1.2–2.4) p = 0.002 | 3.1 (1.1–8.6) p = 0.03 | 9.4 (1.2–76) p = 0.04 | |||
Lymph node involvementb Present vs absent | p = 0.6 | 8.3 (1.8–38) p = 0.006 | p = 0.9 | p = 0.3 | 12.4 (2.8–54) p = 0.001 | p = 0.8 |
ISUP grade group | ||||||
1 | 1 | 1 | 1 | 1 | 1 | 1 |
2 | 1.7 (1.0–2.8) p = 0.04 | p = 0.9 | p = 0.8 | 1.7 (1.0–2.7) p = 0.04 | p = 0.9 | p = 0.8 |
3 | 2.2 (1.2–3.8) p = 0.006 | p = 0.2 | p = 0.6 | 2.1 (1.2–3.6) p = 0.01 | p = 0.2 | p = 0.4 |
4 | p = 0.07 | p = 0.1 | p = 0.9 | 2.3 (1.1–5.1) p = 0.04 | p = 0.1 | p = 0.9 |
5 | p = 0.1 | 6.3 (1.2–32) p = 0.03 | p = 0.2 | p = 0.06 | 7.3 (1.4–37) p = 0.02 | p = 0.1 |
Baseline PSAc, ng/ml | p = 0.6 | p = 0.08 | p = 0.8 | p = 0.6 | p = 0.7 | p = 0.7 |
